WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013156614) METHODS FOR TREATING PARKINSON'S DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/156614    International Application No.:    PCT/EP2013/058212
Publication Date: 24.10.2013 International Filing Date: 19.04.2013
IPC:
A61K 31/395 (2006.01), A61K 31/4439 (2006.01), A61K 31/4523 (2006.01), A61K 31/4985 (2006.01), A61P 25/16 (2006.01)
Applicants: UCB PHARMA S.A. [BE/BE]; 60, Allée de la Recherche B-1070 Brussels (BE)
Inventors: MICHEL, Anne; (BE).
DOWNEY, Patrick; (BE).
MONTEL, Florian; (BE).
SCHELLER, Dieter; (BE).
CHRISTOPHE, Bernard; (BE)
Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Pharma, S.A. 60, Allée de la Recherche B-1070 Brussels (BE)
Priority Data:
61/636,054 20.04.2012 US
Title (EN) METHODS FOR TREATING PARKINSON'S DISEASE
(FR) MÉTHODES DE TRAITEMENT DE LA MALADIE DE PARKINSON
Abstract: front page image
(EN)The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.
(FR)La présente invention concerne une méthode de traitement de la maladie de Parkinson chez un mammifère, comprenant l'administration d'un premier agent pharmaceutique et d'un second agent pharmaceutique. Ledit premier agent pharmaceutique est un antagoniste du récepteur 2 (A2A) de l'adénosine et le second agent pharmaceutique est un antagoniste du récepteur N-méthyl-D-aspartate (NMDA) de sous-type NR2B.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)